{"id":"W2758552192","doi":"10.1016/s1470-2045(17)30566-1","title":"Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Liver physiology and pathology","field":"Medicine","cited_by":343,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"National Institutes of Health; National Cancer Institute; National Institute for Health and Care Research; Amgen","keywords":"Medicine; Capecitabine; Epirubicin; Internal medicine; Placebo; Clinical endpoint; Gastroenterology; Phases of clinical research; Cancer; Chemotherapy; Performance status; Oncology; Surgery; Clinical trial; Pathology; Breast cancer; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001729083,0.0004430652,0.002437392,0.0002506936,0.0005806608,0.00003261821,0.0003786029,0.0003893702,0.0006381185],"category_scores_gemma":[0.0005320557,0.0002622201,0.0001960343,0.0002003175,0.0006376394,0.000204507,0.0001348818,0.0008932771,0.00003563802],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003009876,"about_ca_system_score_gemma":0.0005454305,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005592911,"about_ca_topic_score_gemma":0.001163888,"domain_scores_codex":[0.9968759,0.0007647928,0.0007399282,0.0006567192,0.0002142606,0.0007484143],"domain_scores_gemma":[0.9965499,0.001556125,0.0007646775,0.0007803353,0.0001753906,0.0001735543],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9736636,0.0007407271,0.000938684,0.00002974451,0.0004862285,0.0005201674,0.0008400354,0.0001263533,0.00335719,0.0001350965,0.0004161327,0.01874604],"study_design_scores_gemma":[0.9721026,0.01993509,0.003121294,0.00006520769,0.0004796913,0.0004854845,0.00011728,0.0006849688,0.0005914398,0.0003784129,0.001812311,0.0002261808],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9817064,0.001408832,0.000192184,0.006910056,0.00143329,0.006193274,0.00004313517,0.00005868859,0.002054183],"genre_scores_gemma":[0.9872441,0.003492548,0.0004028747,0.002452306,0.002905823,0.002177921,0.00006906502,0.00004134156,0.00121401],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01919436,"threshold_uncertainty_score":0.999983,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09008277766277609,"score_gpt":0.4101330386963679,"score_spread":0.3200502610335918,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}